Rienk Pypstra

705 total citations · 1 hit paper
11 papers, 380 citations indexed

About

Rienk Pypstra is a scholar working on Infectious Diseases, Epidemiology and Pharmacology. According to data from OpenAlex, Rienk Pypstra has authored 11 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Infectious Diseases, 5 papers in Epidemiology and 4 papers in Pharmacology. Recurrent topics in Rienk Pypstra's work include Antibiotics Pharmacokinetics and Efficacy (4 papers), COVID-19 Clinical Research Studies (4 papers) and Pneumonia and Respiratory Infections (3 papers). Rienk Pypstra is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (4 papers), COVID-19 Clinical Research Studies (4 papers) and Pneumonia and Respiratory Infections (3 papers). Rienk Pypstra collaborates with scholars based in United States, United Kingdom and Switzerland. Rienk Pypstra's co-authors include Gary J. Noel, Joseph S. Solomkin, Karen Amsler, M. Heep, Richard Strauß, Peter Ball, Jennifer Hammond, Thomas P. Lodise, Karen Bush and H. Lode and has published in prestigious journals such as New England Journal of Medicine, Clinical Infectious Diseases and Antimicrobial Agents and Chemotherapy.

In The Last Decade

Rienk Pypstra

11 papers receiving 368 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19

2024 50 citations Jennifer Hammond, Robert J. Fountaine et al. New England Journal of Medicine profile →

Peers

Rienk Pypstra

ID

PHARM

EPIDE

MM

CB

Cristina de la Calle Spain

Kyle C. Molina United States

Paola Della Siega Italy

V. Ramos-Martín United Kingdom

Juliette Patrier France

Akari Shigemi Japan

Giorgio Mosconi Italy

Juan Frasquet Spain

R. Brigg Turner United States

Raymond Yost United States

Cristina de la Calle Spain

Rienk Pypstra

143 ×0.6

ID

69 ×0.4

PHARM

92 ×0.7

EPIDE

58 ×0.5

MM

47 ×0.5

CB

Citations per year, relative to Rienk Pypstra Rienk Pypstra (= 1×) peers Cristina de la Calle

Countries citing papers authored by Rienk Pypstra

Since Specialization

Citations

This map shows the geographic impact of Rienk Pypstra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rienk Pypstra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rienk Pypstra more than expected).

Fields of papers citing papers by Rienk Pypstra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rienk Pypstra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rienk Pypstra. The network helps show where Rienk Pypstra may publish in the future.

Co-authorship network of co-authors of Rienk Pypstra

This figure shows the co-authorship network connecting the top 25 collaborators of Rienk Pypstra. A scholar is included among the top collaborators of Rienk Pypstra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rienk Pypstra. Rienk Pypstra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Hodges, Michael R., Margaret Tawadrous, Oliver A. Cornely, et al.. (2025). Fosmanogepix for the Treatment of Invasive Mold Diseases Caused by Aspergillus Species and Rare Molds: A Phase 2, Open-Label Study (AEGIS). Clinical Infectious Diseases. 81(5). e302–e309. 9 indexed citations

2.

Hammond, Jennifer, Carla Yunis, Robert J. Fountaine, et al.. (2024). Oral Nirmatrelvir–Ritonavir as Postexposure Prophylaxis for Covid-19. New England Journal of Medicine. 391(3). 224–234. 6 indexed citations

3.

Hammond, Jennifer, Robert J. Fountaine, Carla Yunis, et al.. (2024). Nirmatrelvir for Vaccinated or Unvaccinated Adult Outpatients with Covid-19. New England Journal of Medicine. 390(13). 1186–1195. 50 indexed citations breakdown →

4.

Hammond, Jennifer, Annie Gardner, Paula Abreu, et al.. (2024). Alleviation of COVID-19 Symptoms and Reduction in Healthcare Utilization Among High-risk Patients Treated With Nirmatrelvir/Ritonavir (NMV/R): A Phase 3 Randomized Trial. Clinical Infectious Diseases. 80(2). 323–330. 5 indexed citations

5.

Hammond, Jennifer, Annie Gardner, Paula Abreu, et al.. (2022). 786. Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits. Open Forum Infectious Diseases. 9(Supplement_2). 6 indexed citations

6.

Hammond, Jennifer, Annie Gardner, Paula Abreu, et al.. (2022). 1156. Sustained Alleviation and Resolution of Targeted COVID-19 Symptoms with Nirmatrelvir/Ritonavir versus Placebo. Open Forum Infectious Diseases. 9(Supplement_2). 5 indexed citations

7.

Cheng, Karen, Rienk Pypstra, Jean Li Yan, & Jennifer Hammond. (2018). Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h. Journal of Antimicrobial Chemotherapy. 74(4). 1086–1091. 13 indexed citations

8.

Noel, Gary J., Richard Strauß, Karen Amsler, et al.. (2007). Results of a Double-Blind, Randomized Trial of Ceftobiprole Treatment of Complicated Skin and Skin Structure Infections Caused by Gram-Positive Bacteria. Antimicrobial Agents and Chemotherapy. 52(1). 37–44. 146 indexed citations

9.

Lodise, Thomas P., Rienk Pypstra, James B. Kahn, et al.. (2007). Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects. Antimicrobial Agents and Chemotherapy. 51(7). 2378–2387. 60 indexed citations

10.

Wilson, Robert, et al.. (2003). Oral gemifloxacin once daily for 5 days compared with sequential therapy with i.v. ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with acute exacerbations of chronic bronchitis. Respiratory Medicine. 97(3). 242–249. 31 indexed citations

11.

Lode, H., Thomas M. File, Lionel A. Mandell, et al.. (2002). Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: A randomized, open-label, multicenter study of clinical efficacy and tolerability. Clinical Therapeutics. 24(11). 1915–1936. 49 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact